Exome Sequencing utilizes DNA-enrichment methods and massively parallel nucleotide sequencing to identify protein-coding variants in the genome. Together with growing public databases of known variants, exome sequencing allows for identification of genetic mutations and risk factors in samples that were deemed insufficiently informative for previous genetic studies. Not only does exome sequencing enable identification of mutations in families that were undetectable with linkage disequilibrium and positional cloning methods, but is also more rapid and less expensive. The use of exome sequencing has been successful in the characterization of many rare diseases.
EdgeBio’s CLIA Exome Test is now available for clinical laboratories to incorporate into their current testing menu. With access to EdgeBio’s marketing and support, your lab will be empowered to offer cutting edge molecular testing to better serve your patient population. The CLIA Exome is a next generation sequencing test, conducted on the Illumina HiSeq 2000.
-
The complexity of cancer is clearly demonstrated in the diverse ecosystem of the tumor microenvironment (TME). The TME is made up of numerous cell types and its development begins with the changes that happen during oncogenesis. “Genomic mutations, copy number changes, epigenetic alterations, and alternative gene expression occur to varying degrees within the affected tumor cells,” explained Andrea O’Hara, Ph.D., Strategic Technical Specialist at Azenta. “As...07-08-2024, 03:19 PM